Sanofi Tops Pfizer as Number One for Global Pharma Sales

LONDON, November 1, 2011 /PRNewswire/ --

EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Sanofi is expected to take the top spot amongst the world's pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biotechnology specialist Genzyme predicted to help win its number one ranking.

"The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years," commented Dr Jonathan de Pass, chief executive of EvaluatePharma.  "Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest."

For more in-depth analysis and commentary on this news please visit EP Vantage: http://bit.ly/uY5fYm.

                         World's Top 15 Pharma Companies
                                            Rx & OTC pharma sales
                        Market Rank                 ($bn)
                                                                     Annual
                                                                     growth
 
                    2011 2012 2014 2016    2011   2012  2014  2016   2011-16
    Sanofi           3    1    1    1      47.9   51.6  55.4  58.4     4%
    Novartis         2    2    2    2      49.5   49.9  52.2  54.8     2%
    Pfizer           1    3    3    3      54.1   49.8  49.7  51.9    (1%)
    GlaxoSmithKline  5    6    5    4      39.3   41.2  45.6  50.9     5%
    Roche            6    4    4    5      39.1   44.1  46.3  49.0     5%
    Merck & Co       4    5    6    6      42.1   41.9  41.4  43.4     1%
    Johnson &
    Johnson          8    8    7    7      24.8   26.5  29.4  31.5     5%
    AstraZeneca      7    7    8    8      32.0   29.2  27.5  25.7    (4%)
    Teva             12   10   10   9      17.4   20.3  22.5  24.4     7%
    Abbott
    Laboratories     9    9    9    10     22.5   23.5  23.7  24.3     2%
    Bayer            11   12   11   11     18.9   19.7  21.7  23.4     4%
    Takeda           14   13   12   12     17.0   18.2  18.7  20.2     3%
    Bristol-Myers
    Squibb           13   16   17   13     17.1   14.2  15.4  18.9     2%
    Novo Nordisk     17   17   15   14     12.3   13.6  16.4  18.9     9%
    Eli Lilly        10   11   14   15     21.5   20.1  17.6  17.9    (4%)



 

 

About EvaluatePharma Ltd.

The research company EvaluatePharma Ltd was the first to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma® Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage®.

EvaluatePharma®, EvaluatePharma® Alpha, and EP Vantage® are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by EvaluatePharma USA, Inc.

http://www.evaluatepharma.com

Media Contacts:

Andrew Beaven
Marketing Director, EvaluatePharma Ltd
Tel: +44(0)20-7539-1818
Email: andrewb@evaluatepharma.com
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom


 

 

SOURCE EvaluatePharma Ltd

Posted: November 2011


View comments

Hide
(web1)